TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00627640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinimide 50-100 mg/day
Description: Safinamide, (S)-(+)-2-\[4-(3-fluorobenzyloxy) benzylamino\] propanamide methanesulfonate, is an a-aminoamide derivative

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo
Study: NCT04110249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photoacoustic Imaging
Description: Undergo PAI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Acupoint Electrical Stimulation
Description: Undergo ALTENS
Study: NCT01094340

Intervention type: DRUG
Group type: OTHER
Intervention: Thalidomide
Description: fixed dose over 8 clinic visits
Study: NCT02369939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU w1, w5
Study: NCT03952546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saline-coupled Bipolar Sealer
Description: The Aquamantys® System is a commercially available device used routinely used in the operating room for a wide variety of surgical cases. It allows for temperatures to stay at approximately 100°C, nearly 200°C less than conventional devices, which produces a tissue effect without the charring associated with other methods. The temperature is sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels, resulting in the reduction in bleeding from both soft tissue and bone. The device can be used to spot coagulate vessels that are actively bleeding or to broadly paint tissue surfaces to prevent bleeding or treat active oozing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unipolar electrocautery
Description: The Coviden ForceTriad™ energy platform is a full-featured electrosurgical system that provides electrosurgical cutting and coagulation, bipolar functionality, and vessel sealing in a single generator.
Study: NCT00380484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 200µg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 5 mg daily
Study: NCT00224107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: 8 mg daily for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily for 12 weeks
Study: NCT04020237

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education about particulate matter practice score
Description: For the intervention group, specific guidance is given to the patient who might be exposure in environment with higher particulate matter concentration.~* 1) Start air purifier~* 2) Do not go out and make it to the minimum when absolutely necessary~* 3) It is recommended to wear a mask when going out.~* 4) The investigators recommend a lot of water, fresh fruit and vegetables.~* 5) Prepare an inhaler and use it when symptoms get worse.
Study: NCT06031467

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Er, Cr: YSGG laser-assisted non-surgical mechanical therapy
Description: The laser group received mechanical therapy followed by Er;Cr;YSGG laser. Laser application was performed using the bottom-up technique. Therefore, the tip was retracted about 1 mm after it was placed on the bottom of the pocket and slowly moved in the coronal direction to the parallel to the implant surface.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical mechanical therapy
Description: Traditional non surgical mechanical therapy Mechanical instrumentation in all groups was made with titanium curettes.The curette was gently inserted into the peri-implant pocket and the mechanical therapy was completed with threads felt.
Study: NCT00722345

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: review of Canada's Physical Activity Guide for Youth
Description: The contents of the exercise booklet was reviewed with each participant of the control group by the research fellow. Health Canada's Canada's Physical Activity Guide for Youth was used for the exercise booklet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise consultation
Description: The exercise consultation consisted of a one-to-one discussion designed to educate the participant, strengthen his/her motivation and develop realistic goals and strategies to promote physical activity based on the patient's stage of change. The consultation was based upon the standardized protocol previously published by Loughlan and Mutrie. The Consultation Guidelines describe the 5 steps involved in an exercise consultation, including: 1) discussing current \& past activities; 2) reviewing the pros \& cons of exercising; 3) discussing the barriers to exercising and strategies for overcoming them; 4) determining the social support available to the patient; and finally, 5) setting realistic, attainable short term and long term goals to enhance physical activity.
Study: NCT03138512

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nivolumab placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nivolumab placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ipilimumab placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ipilimumab placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab placebo
Description: Specified dose on specified days
Study: NCT00180518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Over-the-wire & Rapid Exchange ACCULINK (tm) Carotid Stent & ACCUNET (tm) embolic protection system
Description: Two rapid exchange devices will be evaluated: the RX ACCUNET Embolic Protection System (RX ACCUNET) and the RX ACCULINK Carotid Stent System (RX ACCULINK).~The RX ACCUNET Embolic Protection System is intended to facilitate the placement of diagnostic and therapeutic devices during interventional procedures and to capture embolic material that may be present during carotid artery interventional procedures.~The RX ACCULINK™ Carotid Stent System is intended for the treatment of carotid artery stenosis in the internal carotid artery (ICA), with or without involvement of the contiguous common carotid artery (CCA), in asymptomatic patients and symptomatic patients.
Study: NCT01554254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127
Description: 300mcg/kg/day, subcutaneous injection for up to 28 days
Study: NCT03434535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technology Intervention
Description: A combination of existing technology and a new app developed by InHealth Measurement Corp to (1) remotely monitor a participant's activity level and weight and (2) remotely provide updates to the participants regarding their progress towards the goals established in the Prostate Cancer Foundation Health and Wellness guidelines.
Study: NCT02496494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus for maintenance immunosupression in kidney transplant recipients
Study: NCT02369939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-FU w1, w5

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: 6x deep regional hyperthermia
Study: NCT00808756

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermentable carbohydrates.
Description: Infant formula enriched with fermentable carbohydrates.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard infant formula.
Description: Standard infant formula.
Study: NCT02131714

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: counseling and exercises
Description: These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character. They also had to perform once daily application of hot packs on both sides of the face for 20 minutes and after that they must perform active free therapeutic exercise of mouth opening for 10 times

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: lifestyle counseling
Study: NCT01154803

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready to Use Therapeutic Food (RUTF)
Description: 1 sachet/day, 500 kcal and multi micronutrients (fortified high quality food(RUTF),for 2 weeks after an illness (malaria, diarrhoea, pneumonia)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Powder (MNP)
Description: 2 sachets / day for 14 days after an illness (diarrheoea, malaria, pneumonia)
Study: NCT03413605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Multilevel CBPR Intervention
Description: The intervention will be implemented through a group-based education workshop. The education session is a curriculum-based group education; each group will be having about 15-20 participants. All group education sessions will take place at collaborating Viet community partners sites, and delivered in Vietnamese language, with offering of refreshment. We will allow 5-7 minutes for participants to get to know each other and to get comfortable talking to the group. Education will have two major topics--- (a) CDC's standard Clinical Preventive Services Guidelines for adults 50+ (CPS). (b) culturally tailored CRC information discussion.
Study: NCT01018823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin oral dosing 1 mg, 5 mg, 25 mg, or 100 mg solutions/suspensions administered once daily for 14 days immediately after breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin oral dosing 1 mg, 5 mg, 25 mg, or 100 mg solutions/suspensions administered once daily for 14 days immediately after breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin oral dosing 1 mg, 5 mg, 25 mg, or 100 mg solutions/suspensions administered once daily for 14 days immediately after breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin oral dosing 1 mg, 5 mg, 25 mg, or 100 mg solutions/suspensions administered once daily for 14 days immediately after breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Ertugliflozin
Description: Placebo oral dosing solutions/suspensions administered once daily for 14 days immediately after breakfast
Study: NCT02420327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch & placebo capsule
Description: On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch & galantamine capsule
Description: On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch & placebo capsule
Description: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch and galantamine capsule
Description: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).
Study: NCT02325726

Intervention type: PROCEDURE
Intervention: Renal Resistive Index compared with NephroCheckTM
Study: NCT02300779

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-residue diet
Description: Subjects will be instructed by members of the research team to follow a low-residue diet for 4 days.~Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.~Fasting will be required from 2 hours after the bowel cleansing is complete. Their usual treatment for diabetes (whether insulin or an oral agent) will be adjusted.
Study: NCT03982693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edetate Disodium
Description: The solution contains up to 3 g of edetate disodium adjusted based on creatinine clearance, 2 g of magnesium chloride, 100 mg of procaine hydrochloride, 2500 U of heparin, 7 g of ascorbate, 2 milliequivalent (mEq) potassium chloride (KCl), 840 mg sodium bicarbonate, 250 mg pantothenic acid, 100 mg of thiamine, 100 mg of pyridoxine, and sterile water to complete 500 mL.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusions consist of 500 ml normal saline.
Study: NCT02300779

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by a liquid-only diet for an additional day.~Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.~Fasting will be required from 2 hours after the bowel cleansing is complete. No modifications in their usual treatment will be made.
Study: NCT00720005

Intervention type: DEVICE
Intervention: Aspheric Acrysof ReSTOR intraocular lens
Description: Bilateral implantation of Aspheric Acrysof ReSTOR
Study: NCT01479088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl
Description: The 6-month pre-treatment period will be followed by a run-in period with a baseline evaluation prior to the drug administration, followed by a 6-month cinacalcet dose titration period, during which the dose will be increased on monthly basis by 0.5 mg/kg or by 30 mg OD up to the achievement of target iPTH value \<180 pg/mL as tolerated by the patient
Study: NCT03796169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal notification
Description: Baseline quality indicators of each endoscopist were measured and those were notified individually.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open notification
Description: Quality indicators were measured for 3 months after 1st interventions and those were notified openly

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Quality indicators were measured for 3 months after 2nd interventions and educated the importance of colonoscopy quality by a GI faculty
Study: NCT04538807

Intervention type: DIAGNOSTIC_TEST
Intervention: electromyography
Description: Electromyography (EMG) is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles.
Study: NCT04360330

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Breast Radiotherapy
Description: Preoperative SABER: Participants will be treated with an assigned dose level of preoperative SABER, delivered in once a day, 5 fractions given on non-consecutive days, over a period of 2 weeks. In this phase I study, starting with dose level II, a dose level of preoperative SABER will be assigned per study dose-escalation design, treating 2 to 6 patients per dose level. The tested doses are the following:~* Dose Level I: 35 Gy (5 fractions of 7 Gy)~* Dose Level II (Starting Dose): 40 Gy (5 fractions of 8 Gy)~* Dose Level III: 45 Gy (5 fractions of 9 Gy)~* Dose Level IV: 50 Gy (5 fractions of 10 Gy)
Study: NCT01332929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5, 10 or 15 mg/kg, IV, on day 1, 15 and 29 plus radiation therapy of the whole brain.~For level 0,1 and 2, a total dose of 30 Gy will be administered in 15 fractions of 2 Gy, from D15 to D33 with 5 fractions a week.~For level 3,a total dose of 30 Gy will be administered in 10 fractions of 3 Gy, from D15 to D26 with 5 fractions a week.
Study: NCT03835208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High/low carbohydrate distribution
Description: A total of 2x3 days, were the patient follow a detailed diet plan. For 3 days they follow a diet plan where the majority of the carbohydrates are located on either the first part of the day(HMK) or the last part of the day(LMK). 4 days of washout are placed between the two interventions. They will not receive food but will be guided by a trained dietitian and the use of a meal plan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High/low carbohydrate distribution
Description: A total of 2x3 days, were the patient follow a detailed diet plan. For 3 days they follow a diet plan where the majority of the carbohydrates are located on either the first part of the day(HMK) or the last part of the day(LMK). 4 days of washout are placed between the two interventions. They will not receive food but will be guided by a trained dietitian and the use of a meal plan.
Study: NCT03421847

Intervention type: DIAGNOSTIC_TEST
Intervention: Rotatory vestibular test
Description: We will measure Depression and Healthy subjects vestibular activity by Rotatory Vestibular tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Rotatory vestibular test
Description: We will measure Depression and Healthy subjects vestibular activity by Rotatory Vestibular tests
Study: NCT01096550

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient
Description: Buprenorphine patients receiving 2 to 8 hours of outpatient counseling.
Study: NCT01381744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flagellin/F1/V
Description: Flagellin/F1/V recombinant fusion protein vaccine administered by the intramuscular route on Days 0 and 28 at a dose of 1, 3, 6, or 10 micrograms (mcg). It is a clear, colorless solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flagellin/F1/V
Description: Flagellin/F1/V recombinant fusion protein vaccine administered by the intramuscular route on Days 0 and 28 at a dose of 1, 3, 6, or 10 micrograms (mcg). It is a clear, colorless solution.
Study: NCT01096550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Outpatient
Description: Buprenorphine patients receiving 9 or more hours of outpatient counseling.
Study: NCT02698592

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CelsiusTMDS® 8 mm catheter
Description: After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with CelsiusTMDS® 8 mm catheter, until complete isthmic block is achieved.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermocool® 3.5 mm catheter of irrigated tip
Description: After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® 3.5 mm catheter of irrigated tip, until complete isthmic block is achieved.
Study: NCT01381744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flagellin/F1/V
Description: Flagellin/F1/V recombinant fusion protein vaccine administered by the intramuscular route on Days 0 and 28 at a dose of 1, 3, 6, or 10 micrograms (mcg). It is a clear, colorless solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flagellin/F1/V
Description: Flagellin/F1/V recombinant fusion protein vaccine administered by the intramuscular route on Days 0 and 28 at a dose of 1, 3, 6, or 10 micrograms (mcg). It is a clear, colorless solution.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline (PBS) used as diluent and placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline (PBS) used as diluent and placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline (PBS) used as diluent and placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline (PBS) used as diluent and placebo.
Study: NCT02059772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micropulse diode laser
Study: NCT02698592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermocool® SF catheter
Description: After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® SF catheter, until complete isthmic block is achieved.
Study: NCT04220866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulevostinag
Description: IT injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT02698761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Care Plan
Description: Care Plan~1. Patient Controlled Analgesia (PCA). PCA will be initiated and managed at the discretion of the Pain Management team.~2. Other Medications. All medications will be given during daytime hours, if possible.~3. Pain Psychology.~4. Physical Therapy. Patient is expected to spend time out of bed by Day 2 participating in light activity.~5. Sleep Hygiene. Patient sleeps between the hours of 10 PM and 5 AM daily. Window blinds open by 8 AM. Patient must be awake and ready to participate in therapy by 9 AM.~6. Extracurricular. TV, phone, computer, and video games only between hours of 4-9 PM (computer okay outside of hours only for school work).~7. Other. Patient will eat meals during regular daytime hours (e.g. breakfast consumed before 9 am) and shower daily.
Study: NCT05675280

Intervention type: OTHER
Intervention: Gluten free diet
Description: All subjects initiated a gluten free diet as mandated by their diagnosis of Celiac disease, regardless of the study

Intervention type: OTHER
Intervention: Gluten free diet
Description: All subjects initiated a gluten free diet as mandated by their diagnosis of Celiac disease, regardless of the study